AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03864965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning
Description: The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
Study NCT03818568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketoanalogues of essential amino acids
Description: Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
Study NCT03818568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketoanalogues of essential amino acids
Description: Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
Study NCT03805139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ajwa Date (phoenix dactylifera)
Description: Effect of Ajwa on Dyslipidemia
Study NCT02979288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus (Lcr 35 regenerans)
Description: Probiotic vaginal tablets vith active probiotic strains
Study NCT02979288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO Intervention
Description: NO Intervention
Study NCT03915379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67571244
Description: JNJ-67571244 will be administered.
Study NCT03928327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Capsules
Study NCT03928327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Oral solution
Study NCT03928327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin Capsules
Study NCT00785629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate
Study NCT00785629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Study NCT00785629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Study NCT00785629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03047681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: venous blood withdrawl
Description: patients will be asked for a venous blood sample
Study NCT02142010 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel liposome injection plus cisplatin
Description: Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
Study NCT04179890 — intervention group
Intervention type: DRUG
Intervention: Afatinib (Gi(l)otrif®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Study NCT04179890 — intervention group
Intervention type: DRUG
Intervention: Erlotinib (Tarceva®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Study NCT04179890 — intervention group
Intervention type: DRUG
Intervention: Gefitinib (IRESSA®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Study NCT04179890 — intervention group
Intervention type: DRUG
Intervention: Osimertinib (Tagrisso®)
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Study NCT04273724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Interventions for Impairments Identified During Geriatric Assessment
Description: Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
Study NCT03574207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
Study NCT04179890 — intervention group
Intervention type: DRUG
Intervention: Afatinib (Gi(l)otrif®)
Description: As first line therapy.
Study NCT04179890 — intervention group
Intervention type: DRUG
Intervention: Osimertinib (Tagrisso®)
Description: In the case the T790M resistance mutation was developed (second line therapy).
Study NCT01748227 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer-Delivered Pain Self-Management
Description: Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
Study NCT02460003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A program of physiotherapy including manual therapy, exercise, pain education.
Study NCT02460003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home exercise program
Study NCT03664739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: IDP-120 Gel, once-daily application
Study NCT03664739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDp-120 Vehicle Gel
Description: IDP-120 Vehicle Gel, once-daily application
Study NCT01770249 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Per-oral Endoscopic Esophagomyotomy (POEM)
Description: The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
Study NCT02922673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02922673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT05368870 — intervention group
Intervention type: PROCEDURE
Intervention: Carlevale implantation
Description: Vitrectomy and Carlevale implantation
Study NCT04254887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EPBD
Description: Small incision of the duodenal nipple + EPBD
Study NCT04254887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EST
Description: Large incision of the duodenal nipple + EPBD
Study NCT00095238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
Study NCT00095238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
Study NCT02632903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT01437995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol Diskus
Description: Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
Study NCT01437995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol Diskus
Description: Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
Study NCT01437995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Diskus
Description: Fluticasone Diskus alone 250 ug twice daily without Salmeterol
Study NCT02457273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC 388
Description: 40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
Study NCT00872027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
Study NCT00872027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills for 8 weeks
Study NCT02922673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02922673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01667848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optitherm® device activated
Description: The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
Study NCT01667848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optitherm® device inactivated
Description: The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
Study NCT01660815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: IV injection, 370 MBq (10mCi), single dose
Study NCT02955329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape tobacco leaves with nicotine out of the PAX device.
Study NCT02955329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana leaves with nicotine out of the PAX device.
Study NCT02955329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAX Loose Leaf Vaporizer
Description: In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
Study NCT03140826 — intervention group
Intervention type: DRUG
Intervention: meropenem
Description: Antibiotics to treat infections.
Study NCT03171922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Diet
Description: ID group have online dietary coach every 2 weeks
Study NCT03171922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic Diet
Description: CD group have every 2 weeks visit at clinic
Study NCT00268814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Description: Diacetylmorphine (i.v.), daily
Study NCT00268814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education and Counselling
Description: Psycho-educational group therapy and individual counselling
Study NCT00268814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education and Counselling
Description: Psycho-educational group therapy and individual counselling
Study NCT00268814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone (p.o.), daily
Study NCT00268814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management and Motivational interviewing
Description: Individual Case Management combined with Motivational interviewing
Study NCT00268814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and Motivational interviewing
Description: Individual Case Management combined with Motivational interviewing
Study NCT02087566 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 600 mg linezolid
Study NCT01610921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchial provocation test
Description: Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
Study NCT04352829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIDEO-TRAINING-SESSION ABOUT MDI USE
Description: The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
Study NCT01091129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry System (treatment with energy)
Description: Treatment with microwave energy delivery device as specified by manufacturer's instructions
Study NCT03804151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitSpirit intervention
Description: The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
Study NCT01307423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20mg twice daily, orally
Study NCT01307423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast 20mg
Description: Apremilast 20mg twice daily, orally
Study NCT01307423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30mg twice daily, orally
Study NCT01307423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast 30mg
Description: Apremilast 30mg twice daily, orally
Study NCT01307423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02413658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Topical use of phenytoin solution on dressings of split thickness skin graft sites.
Study NCT02413658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar solution
Study NCT00942006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 100 mg bid, 14 days
Study NCT00942006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: 2g x 1 iv, 14 days
Study NCT02696083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Therapy System
Study NCT01497392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib lactate
Description: Given PO
Study NCT01497392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01497392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01497392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01497392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01497392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04242537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula oxygen delivery
Description: It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
Study NCT04242537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow nasal cannula oxygen delivery
Description: It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
Study NCT02053974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone
Study NCT01820260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel
Study NCT02053974 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00584974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: 0.5 mg SEP-225289
Study NCT00584974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: 2.0 mg SEP-225289
Study NCT00584974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: 150 mg Venlafaxine
Study NCT00584974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT02095561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV self testing
Description: Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
Study NCT03016611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chewing Ticagrelor LD
Description: 180 mg Chewing Ticagrelor
Study NCT03016611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Prasugrel LD
Description: 60 mg Chewing Prasugrel
Study NCT04687124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
Study NCT04687124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Description: No specified intervention
Study NCT04469491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled type I interferon
Description: The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
Study NCT04469491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WFI water nebulization
Description: The interventional arm includes a WFI water nebulization comparator.
Study NCT02262403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and feces sampling
Description: Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
Study NCT02262403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood and feces sampling
Description: Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
Study NCT04265391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cookies
Description: Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
Study NCT04265391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cookies
Description: Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
Study NCT01967225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (Sivextro, BAY1192631)
Description: BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Study NCT01967225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Study NCT02120417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)
Study NCT02120417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
Study NCT02120417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
Study NCT02120417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo tablets to be administered by mouth
Study NCT03890055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Best supportive care
Study NCT00730236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733
Description: 5-80 mg daily by mouth for 1.5 yrs
Study NCT01962142 — intervention group
Intervention type: OTHER
Intervention: Assessment of activity capacities
Study NCT04391764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone at a dose of 50 mg per day